Company / Accounts Receivable
BioLife Solutions, Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$8.0M
FY2025
5-year range
$7.9M / $33.9M
FY2021-FY2025
Trend
-6.2%
vs FY2024
Sector context
#141 of 143
Health Care
What the data says
Among 143 Health Care companies, BioLife Solutions, Inc. is in the bottom 1% for accounts receivable. Accounts Receivable has fluctuated over the past 10 years, ranging from $1M in FY2017 to $34M in FY2022.
Based on SEC 10-K filings.
$8M in FY2025 with a 5-year CAGR of -0.1%.
Remained stable around $8M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -38.3%
- 5-Year CAGR
- -0.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 143This company $8.0M Sector average $1.3B
▼
-99.4% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.1%, indicating a declining trend.
- In FY2025, accounts receivable decreased 6.2% year-over-year.
- Ranks #141 out of 143 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 4.67 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.0M | -6.2% |
| FY2024 | $8.5M | +7.3% |
| FY2023 | $7.9M | -76.7% |
| FY2022 | $33.9M | +46.2% |
| FY2021 | $23.2M | +190.0% |
| FY2020 | $8.0M | +49.8% |
| FY2019 | $5.3M | +412.5% |
| FY2018 | $1.0M | +2.2% |
| FY2017 | $1.0M | -14.5% |
| FY2016 | $1.2M | +28.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026